ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

ClinicalTrials.gov ID: NCT01462812

Public ClinicalTrials.gov record NCT01462812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 6:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura

Study identification

NCT ID
NCT01462812
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Optinose US Inc.
Industry
Enrollment
223 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Sumatriptan Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
May 31, 2012
Completion
May 31, 2012
Last update posted
May 5, 2015

2011 – 2012

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
San Francisco Clinical Research Center San Francisco California 94109
California Medical Clinic for Headache Santa Monica California 90404
Associated Neurologists of Southern CT, P.C. Fairfied Connecticut 06824
Premiere Research Institute West Palm Beach Florida 33407
MedVadis Watertown Massachusetts 02472
Michigan Head and Pain Institute Ann Arbor Michigan 48104-5199
ClinVest Springfield Missouri 65807
Mercy Health Research St Louis Missouri 63141
DENT Neurologic Institute Amherst New York 14226
Headache Wellnes Center Greensboro North Carolina 27405
PMG Research of Raleigh North carolina, LLC Raleigh North Carolina 27609
PMG Research of Winston Salem, LLC Winston-Salem North Carolina 27103
Neurology Center of Ohio Toledo Ohio 43623
Jefferson Headache Center Philadelphia Pennsylvania 19107
Coastal Carolina Research Center Mt. Pleasant South Carolina 29464

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01462812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2015 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01462812 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →